参考文献/References:
[1]Cavallari L H,Lee CR,Beitelshees AL,et al.Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention[J].JACC Cardiovasc Interv,2018,11(2):181-191.[2]Podda GM,Grossi E,Palmerini T,et al.Prediction of high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndromes[J].Int J Cardiol,2017(240):60-65.[3]Ferreiro JL,Vivas D,De La Hera JM,et al.High and low on-treatment platelet reactivity to P2Y12 inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention[J].Thromb Res,2019(175):95-101.[4]Pereira NL,Rihal CS,So DYF,et al.Clopidogrel Pharmacogenetics[J].Circ Cardiovasc Interv,2019,12(4):e007811.[5]Li X,Wang Z,Wang Q,et al.Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients[J].Basic Clin Pharmacol Toxicol,2019,124(1):84-93.[6]Pereira NL,Farkouh ME,So D,et al.Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial[J].JAMA,2020,324(8):761-771.[7]Gulizia MM,Colivicchi F,Abrignani MG,et al.Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease[J].Eur Heart J Suppl,2018,20(Suppl F):F1-F74.[8]Ferrari M,Tozzi M,Marino F,et al.Clopidogrel pharmacogenetics: associations between genotype and stent thrombosis risk in patients with stent placement[J].J Cardiovasc Med (Hagerstown),2019,20(1):46-48.[9]Li Y,Jing Q,Wang B,et al.Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk.Rationale and design of the OPT-BIRISK double-blinded,placebo-controlled randomized trial[J].Am Heart J,2020(228):1-7.[10]Freynhofer MK,Hein-Rothweiler R,Haller PM,et al.Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study[J].Thromb Haemost,2019,119(4):660-667.[11]Umemura K,Iwaki T.The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers[J].Clin Pharmacol Drug Dev,2016,5(6):480-487.[12]Rodriguez AE,Rodriguez-Granillo AM,Ascarrunz SD,et al.Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials,Registries and Meta-analysis[J].Curr Pharm Des,2018,24(4):465-477.[13]Gimbel M,Qaderdan K,Willemsen L,et al.Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised,open-label,non-inferiority trial[J].Lancet,2020,395(10233):1374-1381.[14]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,361(11):1045-1057.[15]Ueki Y,Bar S,Losdat S,et al.Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores[J].EuroIntervention,2020,16(5):371-379.[16]Szummer K,Montez-Rath ME,Alfredsson J,et al.Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome: Insights From the SWEDEHEART Registry[J].Circulation,2020,142(18):1700-1708.[17]Scott SA,Sangkuhl K,Shuldiner AR,et al.PharmGKB summary: very important pharmacogene information for cytochrome P450,family 2,subfamily C,polypeptide 19[J].Pharmacogenet Genomics,2012,22(2):159-165.[18]Scott SA,Sangkuhl K,Stein CM,et al.Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update[J].Clin Pharmacol Ther,2013,94(3):317-323.[19]El Rouby N,Lima JJ,Johnson JA.Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine[J].Expert Opin Drug Metab Toxicol,2018,14(4):447-460.[20]Man M,Farmen M,Dumaual C,et al.Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans[J].J Clin Pharmacol,2010,50(8):929-940.[21]Jeong YH,Abadilla KA,Tantry US,et al.Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study[J].J Thromb Haemost,2013,11(6):1194-1197.[22]Sienkiewicz-Oleszkiewicz B,Wiela-Hojeńska A.CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugs[J].Pharmazie,2018,73(11):619-624.[23]Liu X,Luo Y,Lai Y,et al.Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome[J].J Genet,2016,95(2):231-237.[24]Ellithi M,Baye J,Wilke RA.CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls[J].Pharmacogenomics,2020,21(12):889-897.[25]Mega JL,Simon T,Collet JP,et al.Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis[J].JAMA,2010,304(16):1821-1830.[26]Siller-Matula JM,Trenk D,Schror K,et al.How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors-is an algorithm the answer?[J].Thromb Haemost,2015,113(1):37-52.[27]Sorich MJ,Rowland A,McKinnon RA,et al.CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis[J].Circ Cardiovasc Genet,2014,7(6):895-902.[28]Huang B,Cui DJ,Ren Y,et al.Effect of cytochrome P450 2C19*17 allelic variant on cardiovascular and cerebrovascular outcomes in clopidogrel-treated patients: A systematic review and meta-analysis[J].J Res Med Sci,2017(22):109.[29]Saydam F,Degirmenci I,Birdane A,et al.The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study[J].Basic Clin Pharmacol Toxicol,2017,121(1):29-36.[30]Li Y,Tang HL,Hu YF,et al.The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients[J].J Thromb Haemost,2012,10(2):199-206.[31]Horenstein RB,Madabushi R,Zineh I,et al.Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers[J].J Clin Pharmacol,2014,54(8):865-873.[32]Mega JL,Hochholzer W,Frelinger AL 3rd,et al.Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease[J].JAMA,2011,306(20):2221-2228.[33]Price MJ,Murray SS,Angiolillo DJ,et al.Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study[J].J Am Coll Cardiol,2012,59(22):1928-1937.[34]Liu GZ,Zhang S,Sun DH,et al.Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study)[J].Eur J Clin Pharmacol,2019,75(8):1059-1068.[35]Klein MD,Williams AK,Lee CR,et al.Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention[J].Arterioscler Thromb Vasc Biol,2019,39(4):647-652.[36]Franchi F,Angiolillo DJ.Novel antiplatelet agents in acute coronary syndrome[J].Nat Rev Cardiol,2015,12(1):30-47.[37]Franchi F,Rollini F,Angiolillo DJ.Antithrombotic therapy for patients with STEMI undergoing primary PCI[J].Nat Rev Cardiol,2017,14(6):361-379.[38]So DY,Wells GA,McPherson R,et al.A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study[J].Pharmacogenomics J,2016,16(1):71-78.[39]Rollini F,Franchi F,Cho JR,et al.A head-to-head pharmacodynamic comparison of prasugrel vs.ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study[J].Eur Heart J,2016,37(35):2722-2730.
相似文献/References:
[1]袁 帅,邢晓博,李 晓,等.MTHFR基因多态性与中年男性冠状动脉病变程度的相关研究[J].医学信息,2018,31(03):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
YUAN Shuai,XING Xiao-bo,LI Xiao,et al.Association of MTHFR Gene Polymorphism with Coronary Artery Lesions in Middle-aged Men[J].Medical Information,2018,31(20):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
[2]张挺挺.经股和桡动脉介入治疗冠心病的临床疗效对比[J].医学信息,2018,31(03):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
ZHANG Ting-ting.Comparison of Clinical Effects of Interventional Treatment of Coronary Heart Disease by Femoral and Radial Artery[J].Medical Information,2018,31(20):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
[3]迮艳华.稳心颗粒联合美托洛尔治疗冠心病心律失常的疗效分析[J].医学信息,2018,31(03):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
ZE Yan-hua.Therapeutic Effect of Wenxin Granule Combined with Metoprolol on Arrhythmia of Coronary Heart Disease[J].Medical Information,2018,31(20):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
[4]张 旭.冠心病心绞痛患者进行护理干预的临床效果及
对护理质量影响研究[J].医学信息,2018,31(05):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
ZHANG Xu.Clinical Effect of Nursing Intervention in Patients with Angina Pectoris of Coronary Heart Disease and its Influence on Nursing Quality[J].Medical Information,2018,31(20):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
[5]向明明,赵晓辉.黑龙江省东部地区汉族人群冠心病的危险因素研究[J].医学信息,2018,31(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
XIANG Ming-ming,ZHAO Xiao-hui.Study on Risk Factors of Coronary Heart Disease in Han Nationality Population in Eastern Heilongjiang Province[J].Medical Information,2018,31(20):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
[6]王 坤,张永春.血清胆红素水平、单核细胞数、红细胞分布宽度与
冠状动脉病变程度的关系[J].医学信息,2018,31(08):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
WANG Kun,ZHANG Yong-chun.Relationship between Serum Bilirubin Level,Monocyte Count,Red Blood Cell Distribution Width and Severity of Coronary Artery Disease[J].Medical Information,2018,31(20):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
[7]毛红岩.冠状动脉介入治疗冠心病的疗效及
对患者血清炎症因子的影响[J].医学信息,2018,31(10):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
MAO Hong-yan.Effect of Coronary Intervention on Coronary Heart Disease and its Influence on Serum Inflammatory Factors[J].Medical Information,2018,31(20):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
[8]杨锦龙,刘 欢,吕秋菊,等.非糖尿病患者糖化血红蛋白和胰岛素抵抗与
冠状动脉病变程度的相关性研究[J].医学信息,2018,31(10):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
YANG Jin-long,LIU Huan,LV Qiu-ju,et al.Correlation between Glycosylated Hemoglobin and Insulin Resistance and Severity of Coronary Artery Disease in Non-diabetic Patients[J].Medical Information,2018,31(20):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
[9]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,31(20):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[10]田跃雷.冠心病介入治疗后再狭窄的中西医防治[J].医学信息,2022,35(09):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]
TIAN Yue-lei.Prevention and Treatment of Restenosis After Percutaneous Coronary Intervention with Chinese and Western Medicine[J].Medical Information,2022,35(20):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]